Inqovi

Patients

Dr Harold Keer, chief medical officer at Taiho Oncology, goes in-depth about why his company places such an emphasis on oral formulations.

News

BeOne gets the nod for BCL2 inhibitor Beqalzi in mantle cell lymphoma, while Taiho's Inqovi has acute myeloid leukaemia added to its label.

News

Pfizer's second-quarter results update is headlined by news of an additional $2.5 billion in cost-cutting initiatives.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.